Viridian Therapeutics, Inc.\DE (VRDN) Depreciation & Amortization (CF) (2013 - 2026)
Viridian Therapeutics, Inc.\DE's (VRDN) quarterly Depreciation & Amortization (CF) came in at $121000.0 in Q1 2026, up 3.42% year-on-year from $117000.0 in Q1 2025, and up 0.83% quarter-over-quarter from $120000.0 in Q4 2025.
Viridian Therapeutics, Inc.\DE (VRDN) Depreciation & Amortization (CF) (2013 - 2026) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Depreciation & Amortization (CF) history runs 14 years deep, the most recent figure standing at $121000.0 for Q1 2026.
- On a quarterly basis, Depreciation & Amortization (CF) rose 3.42% year-over-year to $121000.0 in Q1 2026; TTM through Mar 2026 was $464000.0, a 1.69% decrease from a year earlier, with the FY2025 full-year figure at $460000.0, down 8.0% from the prior year.
- Depreciation & Amortization (CF) grew to $121000.0 in Q1 2026 per VRDN's latest filing, from $120000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $150000.0 in Q4 2023 and bottomed at $40000.0 in Q1 2022.
- The 5-year median for Depreciation & Amortization (CF) is $117000.0 (2025), against an average of $109294.1.
- Across the five-year window, Depreciation & Amortization (CF) soared 700.0% in 2022 and slumped 44.67% in 2024, its largest moves.
- Year by year, Depreciation & Amortization (CF) stood at $96000.0 in 2022, then surged by 56.25% to $150000.0 in 2023, then slumped by 44.67% to $83000.0 in 2024, then surged by 44.58% to $120000.0 in 2025, then gained by 0.83% to $121000.0 in 2026.
- Per Business Quant, the three latest VRDN Depreciation & Amortization (CF) figures stand at $121000.0 (Q1 2026), $120000.0 (Q4 2025), and $110000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Viridian Therapeutics, Inc.\DE | 229.55 Mn | 229.55 Mn | - | 121,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 121,000.00 |
| Mar 31, 2026 | 121,000.00 |
| Dec 31, 2025 | 120,000.00 |
| Dec 31, 2025 | 120,000.00 |
| Sep 30, 2025 | 110,000.00 |
| Sep 30, 2025 | 110,000.00 |
| Jun 30, 2025 | 113,000.00 |
| Jun 30, 2025 | 113,000.00 |
| Mar 31, 2025 | 117,000.00 |
| Mar 31, 2025 | 117,000.00 |
| Dec 31, 2024 | 83,000.00 |
| Dec 31, 2024 | 83,000.00 |
| Sep 30, 2024 | 130,000.00 |
| Sep 30, 2024 | 130,000.00 |
| Jun 30, 2024 | 142,000.00 |
| Jun 30, 2024 | 142,000.00 |
| Mar 31, 2024 | 145,000.00 |
| Mar 31, 2024 | 145,000.00 |
| Dec 31, 2023 | 150,000.00 |
| Dec 31, 2023 | 150,000.00 |